Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/31981
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Atkins R.C. | en |
dc.contributor.author | Kerr P.G. | en |
dc.contributor.author | Pellicano R. | en |
dc.date.accessioned | 2021-05-14T10:49:32Z | en |
dc.date.available | 2021-05-14T10:49:32Z | en |
dc.date.copyright | 2005 | en |
dc.date.created | 20050418 | en |
dc.date.issued | 2005-04-18 | en |
dc.identifier.citation | Kidney International, Supplement. 67 (94) (pp S-101-S-106), 2005. Date of Publication: April 2005. | en |
dc.identifier.issn | 0098-6577 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/31981 | en |
dc.description.abstract | The incidence of end-stage renal disease is increasing at an alarming rate. While diabetes is now the most common cause of renal failure, hypertension commonly coexists, exacerbating renal damage and the other vascular complications of diabetes. Clinical trials have shown the benefits of intervention strategies that target not only the retardation of renal disease, but also the primary prevention of the conditions known to cause renal damage. These strategies include: lifestyle modification programs to prevent diabetes and hypertension; aggressive treatment of established hypertension; combination antihypertensive regimens; and the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for additional renoprotection beyond that of blood pressure control. In addition, albuminuria and proteinuria have emerged as powerful predictors of progression of renal disease. The present paper reviews the results of available clinical trials and meta-analyses on these interventional strategies, and highlights the potential of albuminuria and proteinuria in predicting renal and cardiovascular outcomes. © 2005 by the International Society of Nephrology. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | en |
dc.title | What have we learned from clinical trials on prevention?. | en |
dc.type | Conference Paper | en |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 15752224 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15752224] | en |
dc.identifier.source | 40446508 | en |
dc.identifier.institution | (Pellicano, Kerr, Atkins) Monash Medical Centre, Melbourne, Vic., Australia (Pellicano) Department of Nephrology, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic. 3168, Australia | en |
dc.description.address | R. Pellicano, Department of Nephrology, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic. 3168, Australia. E-mail: rebecca.pellicano@med.monash.edu.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2012 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Diabetes Hypertension Lifestyle modification programs Proteinuria | en |
dc.identifier.authoremail | Pellicano R.; rebecca.pellicano@med.monash.edu.au | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Conference Paper | - |
crisitem.author.dept | Nephrology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.